(Q35601653)

9 August 2017

1 reference

title

Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies (English)

1 reference

9 August 2017

1 reference

David Cameron

1

1 reference

9 August 2017

1 August 2003

1 reference

9 August 2017

1 reference

9 August 2017

12 Suppl 2

1 reference

9 August 2017

S22-9

1 reference

Bisphosphonates: mechanisms of action

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Bisphosphonates induce apoptosis in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Methodology for treatment evaluation in patients with cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Events per person year--a dubious concept

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980160-1

7 January 2021

10.1016/S0960-9776(03)80160-1

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14659140